Jun 10, 2021 04:29 PM

Chinese Embassy in Japan Warns of Vaccine Scams

What’s new: China’s embassy in Japan warned on Wednesday of Covid-19 vaccine scams targeting Chinese citizens in the country, saying Chinese-made vaccines have not been approved for use in the archipelago nation.

The embassy’s statement (link in Chinese) said that people have taken advantage of some Chinese nationals’ eagerness to get a vaccine and have used “fraudulent means” — including pretending to be representatives of the embassy — to obtain personal information through the WeChat chat and social media platform and have accepted payment for vaccines.

“Anyone who obtains personal information, issues registration notices and charges for vaccines in the name of the embassy can be defined as vaccine fraud,” the statement said.

The embassy’s statement didn’t make it clear whether or not shots were actually provided to the paying customers.

Rumors have spread among the Chinese community in Japan that Chinese-made vaccines would be made available to the country’s citizens, the embassy said, but made clear that these were just rumors and urged people not to spread false claims.

What’s more: The embassy said China has rolled out a campaign to “actively assist and strive to” offer global vaccines to Chinese citizens living overseas.

According to data provided by the Our World in Data platform, Japan has administered more than 19 million doses of Covid-19 vaccines so far and 11.5% of its population has recieved at least one dose.

Quick Takes are condensed versions of China-related stories for fast news you can use.

Contact reporter Wang Xintong ( and editor Joshua Dummer (

Download our app to receive breaking news alerts and read the news on the go.

Get our weekly free Must-Read newsletter.

You've accessed an article available only to subscribers
Share this article
Open WeChat and scan the QR code
Get our CX Daily, weekly Must-Read and China Green Bulletin newsletters delivered free to your inbox, bringing you China's top headlines.

We ‘ve added you to our subscriber list.

Manage subscription